Effect of cilobradine in cats with a first episode of congestive heart failure due to primary cardiomyopathy.

INTRODUCTION: Heart rate (HR) is often elevated in cats with cardiomyopathies (CMPs). Pharmacologic modulation of HR may reduce cardiac morbidity and mortality. OBJECTIVES: To investigate the effects of cilobradine vs. placebo, regarding time to cardiac mortality or morbidity in cats with first episode of congestive heart failure (CHF) due to primary CMP. ANIMALS: Three hundred and sixty-seven client-owned cats with primary CMP that had presented with a first episode of CHF at 50 centers in Europe. Per-protocol population comprised 193 cats (n = 89 cilobradine, n = 104 placebo). An interim analysis for futility was planned. METHODS: Prospective, randomized, placebo-controlled, double-blinded, multicenter clinical trial. Primary outcome variable was the time to a composite of cardiac mortality or cardiac morbidity. RESULTS: Median time to primary outcome was 84 days (95% confidence interval [CI]: 63-219 days) in the cilobradine group (CG) and 203 days in the placebo group (95% CI: 145-377 days) with observed hazard ratio of 1.44, indicating a higher hazard for the CG (P = 0.057). Mean HR was 28 beats per minute (bpm) lower at Day 7 (P < 0.0001) and remained 29 bpm lower at Day 360 (P = 0.026) in the CG than that in the placebo group. Although the number of adverse events did not differ, there were more serious adverse events in the CG. CONCLUSIONS: Heart rate reduction by cilobradine in cats with a first episode of CHF due to primary CMP did not reduce cardiac mortality and morbidity.

Rapid assessment with physical examination in dyspnoeic cats: the RAPID CAT study.

OBJECTIVES: To determine the underlying disease prevalence in acute feline dyspnoea and to examine whether historical and clinical examination findings can differentiate between acute cardiac and non-cardiac dyspnoea in cats in primary practice. MATERIALS AND METHODS: We prospectively enrolled cats presenting with dyspnoea for the first time to primary practice between June 1, 2011 and October 31, 2016. We collected signalment, historical and clinical data at presentation using a standard form. Cases were investigated by primary clinicians, and the final diagnosis was confirmed by the authors. Records lacking critical data were excluded. Relationships between historical or clinical variables and dyspnoea aetiology were examined. Diagnostic test performance analyses were used to find optimal cut-off values for select historical or clinical variables that could differentiate cardiac and non-cardiac dyspnoea. RESULTS: Participants included 108 cats. A definitive diagnosis was reached in 92 cases; 60 were cardiac (65%), 15 respiratory (16%), 10 neoplastic (11%) and 7 traumatic (8%). Of cats with cardiac dyspnoea, 25% had a history of cough. A gallop sound, rectal temperature less than 37·5°C, heart rate of greater than 200 bpm and respiratory rate greater than 80 per minute were all useful to predict cardiac-associated dyspnoea. A triage algorithm using these findings in combination was designed to optimise the rapid diagnosis of probable cardiac dyspnoea. CLINICAL SIGNIFICANCE: Dyspnoeic cats presenting in practice with hypothermia, tachycardia, gallop sounds or profound tachypnoea are likely to have a cardiac cause underlying their dyspnoea. Although diagnosis requires confirmation, clinicians may be able to stratify risk and prioritise further investigation based on these findings.

Heart rate turbulence after ventricular premature beats in healthy Doberman pinschers and those with dilated cardiomyopathy.

OBJECTIVES: To describe the measurement of heart rate turbulence (HRT) after ventricular premature beats and compare HRT in healthy Doberman pinschers and those with dilated cardiomyopathy (DCM), with and without congestive heart failure (CHF). ANIMALS: Sixty-five client-owned Dobermans: 20 healthy (NORMAL), 31 with preclinical DCM and 14 with DCM and CHF (DCM + CHF). METHODS: A retrospective study of data retrieved from clinical records and ambulatory ECG (Holter) archives, including data collected previously for a large-scale prospective study of Dobermans with preclinical DCM. Holter data were reanalysed quantitatively, including conventional time-domain heart rate variability and the HRT parameters turbulence onset and turbulence slope. RESULTS: Heart rate turbulence could be measured in 58/65 dogs. Six Holter recordings had inadequate ventricular premature contractions (VPCs) and one exhibited VPCs too similar to sinus morphology. Heart rate turbulence parameter, turbulence onset, was significantly reduced in DCM dogs, whereas conventional heart rate variability measures were not. Heart rate variability and HRT markers were reduced in DCM + CHF dogs as expected. CONCLUSIONS: Heart rate turbulence can be measured from the majority of good quality standard canine 24-hour Holter recordings with >5 VPCs. Turbulence onset is significantly reduced in Dobermans with preclinical DCM which indicates vagal withdrawal early in the course of disease. Heart rate turbulence is a powerful prognostic indicator in human cardiac disease which can be measured from standard 24-hour ambulatory ECG (Holter) recordings using appropriate computer software. Further studies are warranted to assess whether HRT may be of prognostic value in dogs with preclinical DCM and in other canine cardiac disease.

Purring in cats during auscultation: how common is it, and can we stop it?

OBJECTIVES: When cats purr during examination it is difficult to perform auscultation. The objective of this study was to determine the prevalence of purring in cats during examination, and identify interventions that could be used to stop purring. METHODS: Cats seen at a first opinion clinic were enrolled in the study and their purring status recorded. Thirty of the purring cats were exposed to up to three different interventions in an attempt to stop purring in a randomised controlled trial including blowing at the ear, use of an ethanol-based aerosol near the cat and proximity to a running tap. RESULTS: The 30 cats in the trial were subjected to a total of 54 attempts to stop purring, proximity to a running tap caused 17 of 21 (81%) cats to stop purring, blowing at the cat's ears worked in 2 of 15 (13%) cats, spraying an aerosol close to the cat was effective in 9 of 18 (50%) cases. In 2 cats (7%), none of the interventions interrupted purring. CLINICAL SIGNIFICANCE: This study provides evidence that placing a purring cat near a running tap and in proximity to the discharge of an ethanol-based aerosol are effective measures to stop purring in order to allow auscultation.

Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.

BACKGROUND: Myxomatous mitral valve disease (MMVD) is an important cause of morbidity and mortality in dogs. OBJECTIVES: To compare, throughout the period of follow-up of dogs that had not yet reached the primary endpoint, the longitudinal effects of pimobendan versus benazepril hydrochloride treatment on quality-of-life (QoL) variables, concomitant congestive heart failure (CHF) treatment, and other outcome variables in dogs suffering from CHF secondary to MMVD. ANIMALS: A total of 260 dogs in CHF because of MMVD. METHODS: A prospective single-blinded study with dogs randomized to receive pimobendan (0.4-0.6 mg/kg/day) or benazepril hydrochloride (0.25-1.0 mg/kg/day). Differences in outcome variables and time to intensification of CHF treatment were compared. RESULTS: A total of 124 dogs were randomized to pimobendan and 128 to benazepril. No difference was found between groups in QoL variables during the trial. Time from inclusion to 1st intensification of CHF treatment was longer in the pimobendan group (pimobendan 98 days, IQR 30-276 days versus benazepril 59 days, IQR 11-121 days; P = .0005). Postinclusion, dogs in the pimobendan group had smaller heart size based on VHS score (P = .013) and left ventricular diastolic (P = .035) and systolic (P = .0044) dimensions, higher body temperature (P = .030), serum sodium (P = .0027), and total protein (P = .0003) concentrations, and packed cell volume (P = .030). Incidence of arrhythmias was similar in treatment groups. CONCLUSIONS AND CLINICAL IMPORTANCE: Pimobendan versus benazepril resulted in similar QoL during the study, but conferred increased time before intensification of CHF treatment. Pimobendan treatment resulted in smaller heart size, higher body temperature, and less retention of free water.

Lack of correlation between canine heart rate and body size in veterinary clinical practice.

OBJECTIVES: An association between heart rate (HR) and bodyweight has been reported in dogs and it is common belief that small breeds of dog exhibit higher HR than large breeds. The first aim of this study was to test the null hypothesis that, in veterinary clinical practice, bodyweight does not affect HR measured in healthy dogs. A second objective of this investigation was to assess whether other variables, such as gender, breed morphology, age and demeanour, may have a significant effect on dog's HR measured in a clinical setting. METHODS: The investigation was performed via two different studies: a retrospective analysis performed on 243 electrocardiogram recordings and a prospective study based on 153 standardised clinical examinations. RESULTS: The two separate studies did not show any significant correlation between HR and bodyweight (P=0.5705 and P=0.4682, respectively). Subject's breed morphology and gender did not appear to affect HR measured under these circumstances. However, dogs under the age of one year seem to have significantly higher HRs than older dogs (P < 0.05). Finally, subject's demeanour was also found to have a significant influence on HR; lower values were recorded in relaxed dogs, and higher rates were documented in excited, nervous dogs (P < 0.05). CLINICAL SIGNIFICANCE: Normal HR could be erroneously interpreted as bradycardia or tachycardia if bodyweight was to be considered a determinant factor. Instead, HR in healthy dogs undergoing routine clinical examination is related to their demeanour or age, if younger than 12 months, but does not appear to be related to bodyweight.

Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.

BACKGROUND: Myxomatous mitral valve disease (MMVD) continues to be an important cause of morbidity and mortality in geriatric dogs despite conventional therapy. HYPOTHESIS: Pimobendan in addition to conventional therapy will extend time to sudden cardiac death, euthanasia for cardiac reasons, or treatment failure when compared with conventional therapy plus benazepril in dogs with congestive heart failure (CHF) attributable to MMVD. ANIMALS: Two hundred and sixty client-owned dogs in CHF caused by MMVD were recruited from 28 centers in Europe, Canada, and Australia. METHODS: A prospective single-blinded study with dogs randomized to PO receive pimobendan (0.4-0.6 mg/kg/d) or benazepril hydrochloride (0.25-1.0 mg/kg/d). The primary endpoint was a composite of cardiac death, euthanized for heart failure, or treatment failure. RESULTS: Eight dogs were excluded from analysis. One hundred and twenty-four dogs were randomized to pimobendan and 128 to benazepril. One hundred and ninety dogs reached the primary endpoint; the median time was 188 days (267 days for pimobendan, 140 days for benazepril hazard ratio = 0.688, 95% confidence limits [CL]=0.516-0.916, P= .0099). The benefit of pimobendan persisted after adjusting for all baseline variables. A longer time to reach the endpoint was also associated with being a Cavalier King Charles Spaniel, requiring a lower furosemide dose, and having a higher creatinine concentration. Increases in several indicators of cardiac enlargement (left atrial to aortic root ratio, vertebral heart scale, and percentage increase in left ventricular internal diameter in systole) were associated with a shorter time to endpoint, as was a worse tolerance for exercise. CONCLUSIONS AND CLINICAL IMPORTANCE: Pimobendan plus conventional therapy prolongs time to sudden death, euthanasia for cardiac reasons, or treatment failure in dogs with CHF caused by MMVD compared with benazepril plus conventional therapy.

Heart failure is common in diabetic cats: findings from a retrospective case-controlled study in first-opinion practice.

OBJECTIVES: To study the prognosis and cause of death in cats with diabetes mellitus. METHODS: Twenty consecutive cases of feline diabetes mellitus diagnosed in first-opinion practice were followed. Three control cats, without diabetes, were matched to each case of diabetes; these were also followed. RESULTS: One Somali cat with diabetes could not be matched, so complete data analysis considered only 19 diabetics and 57 matched controls. Death occurred in 14 of 20 diabetics and 23 of 57 controls although one control cat was eventually lost to follow-up. Heart disease and heart failure led to death in six diabetic cats. One of these was the non-matched Somali; nevertheless, the death rate from heart disease in the diabetics was five of 19 compared with two of 57 in controls. The relative risk of heart failure in diabetic cats was 10.4 times that of the controls; this difference in rates was statistically significant. Survival amongst diabetics was significantly worse than for controls. For the control cats median survival was 718 days after the index visit, whereas for the diabetic cases median survival was 385 days after diagnosis. CLINICAL SIGNIFICANCE: Heart disease and failure are common in diabetic cats. This observation deserves further attention.

Heart failure in two West Highland white terriers caused by congenital angiomatous cardiac anomaly.

The paper describes the clinical and pathological characteristics of an unusual cystic congenital cardiac anomaly that caused clinical signs of congestive heart failure, respiratory distress and cardiac arrhythmias in two West Highland white terrier puppies. In both dogs a definitive diagnosis was made postmortem.

Hypoglycaemic bradycardia and circulatory collapse in a dog and a cat.

Hypoglycaemia was accompanied by sinus bradycardia and circulatory collapse in a dog and a cat. In each case, when the hypoglycaemia was corrected by intravenous infusion of a glucose solution the bradycardia and circulatory failure were soon abolished, indicating that these abnormalities were caused by the hypoglycaemia. Similar observations have been made in human patients. To the author's knowledge, this is the first report documenting hypoglycaemic bradycardia in veterinary medicine.

Non-invasive real-time measurements of cardiac vagal tone in dogs with cardiac disease.

In dogs with spontaneous heart disease, an electronically generated measurement of cardiac vagal tone, the cardiac index of parasympathetic activity, was a sensitive, simple and inexpensive measure of the severity of heart failure. Dogs with cardiac disease and an index score less than 3 were at 15.8 (95 per cent confidence interval 2.9 to 87.2) times the risk of dying within a year than those with a score of 3 and over. The measurement of the index provided an objective and reliable beat-by-beat measurement of cardiac vagal tone, which was prognostically useful in dogs with heart disease.